JP Morgan Chase’s BioNTech BNTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.89M Sell
20,000
-23,000
-53% -$2.16M ﹤0.01% 4236
2026
Q1
$3.67M Buy
43,000
+26,900
+167% +$2.76M ﹤0.01% 3607
2025
Q4
$1.53M Sell
16,100
-100
-0.6% -$10.1K ﹤0.01% 4306
2025
Q3
$1.6M Buy
16,200
+1,200
+8% +$128K ﹤0.01% 4247
2025
Q2
$1.6M Hold
15,000
﹤0.01% 4081
2025
Q1
$1.37M Hold
15,000
﹤0.01% 4133
2024
Q4
$1.71M Hold
15,000
﹤0.01% 4265
2024
Q3
$1.78M Buy
+15,000
New +$1.38M ﹤0.01% 4087
2023
Q3
Sell
-6,500
Closed -$702K 7471
2023
Q2
$702K Buy
+6,500
New +$731K ﹤0.01% 4292
2023
Q1
Sell
-6,000
Closed -$901K 6702
2022
Q4
$901K Hold
6,000
﹤0.01% 4118
2022
Q3
$809K Hold
6,000
﹤0.01% 4159
2022
Q2
$895K Sell
6,000
-45,000
-88% -$6.88M ﹤0.01% 4181
2022
Q1
$8.7M Sell
51,000
-354,500
-87% -$59.6M ﹤0.01% 2511
2021
Q4
$105M Buy
405,500
+322,500
+389% +$88.3M 0.01% 862
2021
Q3
$22.7M Buy
83,000
+58,800
+243% +$18.7M ﹤0.01% 1663
2021
Q2
$5.42M Sell
24,200
-25,700
-52% -$4.85M ﹤0.01% 2980
2021
Q1
$5.45M Buy
+49,900
New +$5.3M ﹤0.01% 2889
2020
Q3
Sell
-31,700
Closed -$2.12M 5483
2020
Q2
$2.12M Buy
+31,700
New +$1.58M ﹤0.01% 3067

Other funds holding BNTX

JP Morgan Chase's BNTX Position: Q2 2026 in Review

JP Morgan Chase increased its BioNTech (BNTX) stake by 8.3% in Q2 2026, buying an estimated $914K and bringing the position to 126,975 shares worth $12M. The position accounts for ﹤0.01% of the portfolio, ranked #2649.

JP Morgan Chase first reported a position in BNTX in Q1 2020 and has held it in 26 quarters since. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

  • JP Morgan Chase held 126,975 shares of BioNTech worth $12M as of Q2 2026.
  • JP Morgan Chase bought 9,707 BioNTech shares in Q2 2026, an estimated $914K.
  • BioNTech made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2649 holding.
  • JP Morgan Chase first reported a position in BioNTech in Q1 2020 and has held it in 26 quarters since.
  • 282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.